opt-302
Recombinant proteinexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02543229)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- opt-302
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04757610 | Phase 3 | Mar 12, 2021 | Opthea Pty Ltd. |
| NCT04757636 | Phase 3 | Mar 12, 2021 | Opthea Pty Ltd. |
| NCT03397264 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2017 | Opthea Pty Ltd. |
| NCT03345082 | Phase 2 | Nov 6, 2017 | Opthea Pty Ltd. |
| NCT02543229 | Phase 1 | Jul 1, 2015 | Opthea Pty Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Opthea Pty Ltd. | For profit | 5 | 5 | 3 | 2015 |
1 organizations
Page 1 / 1